Logo image of BCAX

BICARA THERAPEUTICS INC (BCAX) Stock Fundamental Analysis

NASDAQ:BCAX - Nasdaq - US0554771032 - Common Stock - Currency: USD

10.23  +0.05 (+0.49%)

After market: 10.23 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BCAX. BCAX was compared to 558 industry peers in the Biotechnology industry. BCAX has a great financial health rating, but its profitability evaluates not so good. BCAX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BCAX has reported negative net income.
BCAX Yearly Net Income VS EBIT VS OCF VS FCFBCAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -21.93%, BCAX is doing good in the industry, outperforming 77.06% of the companies in the same industry.
BCAX's Return On Equity of -22.84% is amongst the best of the industry. BCAX outperforms 82.80% of its industry peers.
Industry RankSector Rank
ROA -21.93%
ROE -22.84%
ROIC N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAX Yearly ROA, ROE, ROICBCAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 200 -200 -400

1.3 Margins

BCAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAX Yearly Profit, Operating, Gross MarginsBCAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

BCAX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAX Yearly Shares OutstandingBCAX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
BCAX Yearly Total Debt VS Total AssetsBCAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

BCAX has an Altman-Z score of 17.03. This indicates that BCAX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 17.03, BCAX belongs to the top of the industry, outperforming 92.65% of the companies in the same industry.
BCAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.03
ROIC/WACCN/A
WACCN/A
BCAX Yearly LT Debt VS Equity VS FCFBCAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 24.62 indicates that BCAX has no problem at all paying its short term obligations.
BCAX has a Current ratio of 24.62. This is amongst the best in the industry. BCAX outperforms 95.88% of its industry peers.
BCAX has a Quick Ratio of 24.62. This indicates that BCAX is financially healthy and has no problem in meeting its short term obligations.
BCAX has a better Quick ratio (24.62) than 95.88% of its industry peers.
Industry RankSector Rank
Current Ratio 24.62
Quick Ratio 24.62
BCAX Yearly Current Assets VS Current LiabilitesBCAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for BCAX have decreased strongly by -302.87% in the last year.
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCAX will show a decrease in Earnings Per Share. The EPS will decrease by -2.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.88%
EPS Next 2Y-2.59%
EPS Next 3Y-2.85%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BCAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAX Price Earnings VS Forward Price EarningsBCAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAX Per share dataBCAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

BCAX's earnings are expected to decrease with -2.85% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.59%
EPS Next 3Y-2.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BICARA THERAPEUTICS INC

NASDAQ:BCAX (7/15/2025, 8:00:01 PM)

After market: 10.23 0 (0%)

10.23

+0.05 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)N/A N/A
Inst Owners81.44%
Inst Owner Change0%
Ins Owners1.46%
Ins Owner Change0%
Market Cap557.94M
Analysts83.08
Price Target33.25 (225.02%)
Short Float %13.06%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.45%
Min EPS beat(2)-60.69%
Max EPS beat(2)-18.22%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.54%
EPS NY rev (1m)-15.15%
EPS NY rev (3m)-40.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-4.75
EYN/A
EPS(NY)-2.79
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.42
TBVpS8.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.93%
ROE -22.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.62
Quick Ratio 24.62
Altman-Z 17.03
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1710.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y6.88%
EPS Next 2Y-2.59%
EPS Next 3Y-2.85%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-106.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-113.69%
EBIT Next 3Y-38.63%
EBIT Next 5YN/A
FCF growth 1Y-61.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.83%
OCF growth 3YN/A
OCF growth 5YN/A